Chris Heberlig has more than two decades of financial, strategic and operational experience in the biotechnology industry with a background supporting companies advancing from private to public markets and from early-stage development towards commercialization. Prior to KSQ, Chris served as Executive Vice President, Chief Financial Officer at Kiniksa Pharmaceuticals, where he was part of the founding team that in-licensed a portfolio of products. During his time at Kiniksa he helped raise over $500 million in private and public equity financing, including an initial public offering, as part of progressing the company’s programs. Prior to Kiniksa, he served as Senior Vice President of Finance and Business Operations and Chief Accounting Officer at Synageva BioPharma Corp. supporting the company’s transition to the public markets, raising more than $1 billion in new capital and significant organizational growth. Earlier in his career Chris held financial leadership roles at Panacos Pharmaceuticals Inc. and EPIX Pharmaceuticals Inc., both publicly traded biotechnology companies. Chris began his career at PwC, a national audit, tax and advisory services firm. He received an MBA from Boston University and a BA in economics from St. Lawrence University.